ChemGenex welcomes Cephalon as new investor
22 October, 2010 by David BinningMelbourne cancer biotech ChemGenex announced today that US pharma Cephalon has become a major new investor in the company. The announcement saw the company’s shares surge almost 15 percent to $0.50 by mid afternoon trade.
Gene patent debate "muddled": panel
22 October, 2010 by Tim DeanThe gene patenting debate is complex, says Tania Obranovich, partner at law firm Davis Collison Cave, who spoke yesterday at the AusBiotech 2010 Conference on a panel entitled ‘Busting the myths about gene patenting.’
Agilent kicks off two partnerships with Australian universities
20 October, 2010 by Staff WritersTwo Australian universities have received funding and technology from Agilent Technologies to help kick start new research initiatives.
Feature: Australian Synchrotron transforms proteomics
08 October, 2010 by Graeme O'NeillMelbourne X-ray crystallographer, Tom Caradoc-Davies, needed only one hour on the Australian Synchrotron’s beamline to obtain the high-resolution diffraction data that revealed the structure of a key component of bacterial pili.
Human Proteome Project launches in Sydney
23 September, 2010 by Tim DeanIt’s the Next Big Thing in understanding human biology and the natural successor to the Human Genome Project. It’s the Human Proteome Project (HPP), and it was launched this morning by some of the leading figures in proteomics to a room filled with Australian an international delegates attending the HUPO World Congress in Darling Harbour in Sydney.
Feature: Mitochondrial mysteries
20 September, 2010 by Staff WritersThey are diseases most people haven’t heard of: Kearns-Sayre syndrome; Leber’s hereditary optic neuropathy; Leigh syndrome or mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS).
Australian researchers find blindness genes
19 September, 2010 by Staff WritersStudies of twins conducted at the Queensland Institute of Medical Research (QIMR) has revealed a number of genes that appear to affect eyesight.
Feature: Quest for the human proteome
14 September, 2010 by Tim DeanMapping the human genome, and its 21,000-odd protein-coding genes, was a mammoth undertaking, requiring a 10 year, multi-billion dollar, collaborative effort by teams from across the globe. Yet the Human Genome Project (HGP) was only the beginning. In Sydney in September, at the Human Proteome Organisation (HUPO) Annual World Congress, the next great undertaking in uncovering the foundations of human biology will begin, with the official launch of the Human Proteome Project.
Search for asthma gene gets serious down under
08 September, 2010 by Staff WritersThe largest ever Australian study looking into the genetic causes of asthma is about to get under way.
Search for asthma gene gets serious down under
08 September, 2010 by Staff WritersThe largest ever Australian study looking into the genetic causes of asthma is about to get under way.
Feature: Proteomics power of pawpaw
07 September, 2010 by Kate McDonaldIt may sound like the spiel of a snake-oil salesman, but the story behind the development of a new Australian product derived from an extract of pawpaw (Carica papaya) designed to promote wound healing is a compelling one. The Australian company behind it, Phoenix Eagle, has developed a new product, OPAL A, that could revolutionise wound healing and wound care.
Researchers find migraine gene
03 September, 2010 by David BinningAn international group of researchers has identified what might be the first known genetic indicator for migraine risk.
Feature: Diagnosing Darwin
01 September, 2010 by Graeme O'NeillIn January last year, Dr John Hayman read a biography of Charles Darwin and became intrigued by Darwin’s almost lifelong battle with a chronic, relapsing illness. But now, Hayman, an Associate Professor in Monash University’s Department of Pathology, thinks he’s narrowed it down to a rare mitochondrial disorder inherited from his mother.
Feature: Next next generation sequencing
26 August, 2010 by Staff WritersIt took nearly two decades to go from the release of the first semi-automated genome sequencer in the mid-1980s to the launch of Roche's flagship 454 FLX next generation sequencer in 2005. The 454 is now one of three major players in the next gen market whose impact on the world of genomics cannot be underestimated. Just five years later we are poised to embrace the next generation of sequencing technology.
Genes linked to cholesterol and heart disease discovered
05 August, 2010 by Tim DeanCardiovascular disease (CVD) is the leading cause of death in Australia, with the National Health and Medical Research Council (NHMRC) estimating it costs Australia $5.9 billion in 2004-2005.
